UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2025
Commission File Number: 001-36582
Altamira Therapeutics Ltd.
(Exact name of registrant as specified in its charter)
Clarendon House, 2 Church Street
Hamilton HM 11, Bermuda
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Altamira Therapeutics Ltd. | ||
| Date: May 9, 2025 | By: | /s/ Thomas Meyer |
| Name: | Thomas Meyer | |
| Title: | Chief Executive Officer | |
1
EXHIBIT INDEX
| Exhibit Number |
Description | |
| 99.1 | Notice to Shareholders dated May 9, 2025 | |
| 99.2 | Proxy Card for the Annual General Meeting of Shareholders | |
| 99.3 | Notice of Internet Availability |
2